Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: Development of a prediction model

Lancet Oncology

Volumn 6, Issue 11, 2005, Pages 856-863

  Dranitsaris, George ^a,d   Clemons, Mark ^a   Verma, Sunil ^a   Lau, Cathy ^c   Vincent, Mark ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c Ortho Biotech   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; METHOHEXITAL; METHOTREXATE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACCURACY; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOLOGY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SAMPLE SIZE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; THROMBOCYTE COUNT; VALIDATION PROCESS;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EPOETIN ALFA; FEMALE; FILGRASTIM; HEMATINICS; HUMANS; LOGISTIC MODELS; MEDICAL RECORDS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE;

EID: 27744582735     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70394-6     Document Type: Article

References (23)

1. MJ Ratain Pharmacology of cancer chemotherapy: Pharmacokinetics and pharmacodynamics In: Devita VT Hellman S Rosenberg SA eds. Cancer: principles and practice of oncology 6th edn. 2001 Lippincott Williams & Wilkins Philadelphia 335-344
2. ME de Jonge AD Huitema JH Schellens et al. Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review Clin Pharmacokinet 44 2005 147-173
3. A Rousseau P Marquet J Debord et al. Adaptive control methods for the dose individualisation of anticancer agents Clin Pharmacokinet 38 2000 315-353
4. J Bradbury Docetaxel downside highlighted Lancet Oncol 6 2005 447
5. E Cortesi P Gascon D Henry et al. Standard of care for cancer-related anaemia: Improving haemoglobin levels and quality of life Oncology 68 suppl 1 2005 22-32
6. GH Lyman ER Berndt JD Kallich et al. The economic burden of anaemia in cancer patients receiving chemotherapy Value Health 8 2005 149-156
7. NL Krupp G Weinstein A Chalian Validation of a transfusion prediction model in head and neck cancer surgery Arch Otolaryngol Head Neck Surg 129 2003 1297-1302
8. S Benoist Y Panis V Pannegeon et al. Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients Surgery 129 2001 433-439
9. D Heddens DS Alberts EV Hannigan et al. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment Gynecol Oncol 86 2002 239-243
10. MN Levine VH Bramwell KI Pritchard et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer J Clin Oncol 16 1998 2651-2658
11. SL George Identification and assessment of prognostic factors Semin Oncol 15 1988 462-471
12. J Klastersky M Paesmans EB Rubenstein et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 2000 3038-3051
13. J Chang F Couture S Young et al. Weekly epoetin alfa maintains haemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy J Clin Oncol 23 2005 2597-2605
14. MR Nowrousian Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours Med Oncol 15 suppl 1 1998 S19-S28
15. B Coiffier JP Guastalla E Pujade-Lauraine P Bastit Anaemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey Eur J Cancer 37 2001 1617-1623
16. JL Spivak The anaemia of cancer: Death by a thousand cuts Nat Rev Cancer 5 2005 543-555
17. JH Silber M Fridman RS DiPaola et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy J Clin Oncol 16 1998 2392-2400
18. E Rivera M Haim Erder M Fridman et al. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: A validation study Breast Cancer Res 5 2003 R114-R120
19. GH Lyman Risk assessment in oncology clinical practice. From risk factors to risk models Oncology 17 suppl 11 2003 8-13
20. JT Estrin L Schocket R Kregenow DH Henry A retrospective review of blood transfusions in cancer patients with anaemia Oncologist 4 1999 318-324
21. T Seshadri HM Prince DR Bell et al. Australian Cancer Anaemia Study Group. The Australian Cancer Anaemia Survey: A snapshot of anaemia in adult patients with cancer Med J Aust 182 2005 453-457
22. R Stasi S Amadori TJ Littlewood et al. Management of cancer-related anaemia with erythropoietic agents: Doubts, certainties, and concerns Oncologist 10 2005 539-554
23. Anon Pre-treatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients Curr Med Res Opin 21 suppl 2 2005 S19-S21